Minneslate Logo

HF2482 (Legislative Session 94 (2025-2026))

Health care utilization review provisions and prior authorization clinical criteria applicability modified.

Related bill: SF2607

AI Generated Summary

Purpose of the Bill

This bill aims to modify how changes in prior authorization clinical criteria and utilization review provisions are applied within the health care system in Minnesota. Specifically, it addresses the timing and conditions under which these changes affect health service coverage.

Main Provisions

  • Postponing Changes: If a utilization review organization changes coverage terms or clinical criteria for a health care service within a plan or calendar year, these changes will not apply until the next plan year or calendar year. This rule protects patients who have already received prior authorization based on the existing criteria.

  • Exceptions to Postponement:

    • The aforementioned postponement does not apply if the U.S. Food and Drug Administration (FDA) deems a drug or device unsafe or if it is withdrawn by the manufacturer or FDA.
    • It also does not apply if an independent source recommends changes in service usage for reasons of patient harm. This specific exception is subject to expire on December 31, 2025, but will continue under conditions of previously unknown and imminent patient harm beginning January 1, 2026.
    • Additionally, changes are allowed if a brand-name drug is removed from a formulary and replaced with a therapeutically equivalent generic or multisource brand-name drug at a lower cost, provided certain notifications are given.

  • Notification Requirements: Utilization review organizations must provide a 60-day notice to prescribers, pharmacists, and affected enrollees when removing or changing the category of a brand-name drug.

Significant Changes to Existing Law

  • The bill amends the Minnesota Statutes to specify how and when utilization review changes apply, introducing clear guidelines and exceptions.
  • From January 1, 2026, specific provisions of chapter 62M will apply to the state's human services commissioner, ensuring consistency in how services are delivered under the MinnesotaCare and Medicaid programs (chapters 256B and 256L).

Relevant Terms

prior authorization, clinical criteria, utilization review, health care service, coverage terms, FDA, drug safety, formulary, generic drug, brand-name drug, MinnesotaCare, Medicaid, patient harm.

Bill text versions

Actions

DateChamberWhereTypeNameCommittee Name
March 16, 2025HouseFloorActionIntroduction and first reading, referred toHuman Services Finance and Policy
March 19, 2025HouseFloorActionMotion to recall and re-refer, motion prevailedHealth Finance and Policy

Citations

 
[
  {
    "analysis": {
      "added": [
        "Provisions for expiration and applicability related to changes in service usage due to patient harm."
      ],
      "removed": [],
      "summary": "The bill modifies rules regarding the effect of changes in prior authorization clinical criteria under section 62M.17.",
      "modified": [
        "Clarification on exceptions where prior authorization change rules do not apply."
      ]
    },
    "citation": "62M.17"
  },
  {
    "analysis": {
      "added": [
        "Specification of applicability dates for certain utilization review provisions."
      ],
      "removed": [],
      "summary": "This bill amends the applicability of utilization review provisions under section 256B.0625.",
      "modified": [
        "Clarification regarding applicable provisions for the commissioner when delivering services under chapters 256B and 256L."
      ]
    },
    "citation": "256B.0625"
  }
]

Sponsors